Lead candidate Nefecon (a targeted-release budesonide formulation) is positioned, if approved, to transform the treatment of IgAN. Today, the 130,000–150,000 people estimated to suffer from this ...

花旗发表报告指，与云顶新耀举行了最新会议，管理层指导2025年销售额为14亿元，包括Nefecon的10亿元和Xerava的4亿元。而Nefecon已成功纳入国家医保。

Nefecon is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass ...

Data from a new randomized, placebo-controlled trial have demonstrated the efficacy of budesonide in inducing remission of this disease; this study is an important contribution to this field.

Nefecon is a formulation of the established immunology drug budesonide that dissolves only when it reaches the ileum – the last part of the intestine. This stops organs in the ileum wall known ...

About NEFECON(R) NEFECON(R) is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes ...